TY - JOUR
T1 - Use of glucosamine and chondroitin and lung cancer risk in the VITamins and Lifestyle (VITAL) cohort
AU - Brasky, Theodore M.
AU - Lampe, Johanna W.
AU - Slatore, Christopher G.
AU - White, Emily
N1 - Funding Information:
Acknowledgments This work is supported in part by grants R25-CA94880, R01-CA142545, and K05-CA154337 from the National Institutes of Health, National Cancer Institute. Dr. Slatore’s work on this project was supported with resources and the use of facilities at the Portland VA Medical Center.
PY - 2011/9
Y1 - 2011/9
N2 - Objective: Inflammation plays an important role in lung carcinogenesis. Epidemiologic studies have reported inverse associations of non-steroidal anti-inflammatory drug (NSAID) use and lung cancer risk. Previously, we found that ever use of glucosamine and chondroitin, which have anti-inflammatory properties, were inversely associated with lung cancer risk. After an additional year of follow-up, we further examined the association including frequency/duration of use, interaction with factors associated with inflammation, and lung cancer histology. Methods: Participants were members of the VITamins And Lifestyle cohort. Adults, aged 50-76 years, who were residents of western Washington State, completed a baseline questionnaire in 2000-2002 (n = 76,904). Participants were queried on their use of glucosamine and chondroitin, over the 10 years prior to baseline, and categorized as nonuser, low use <4 days/week or <3 years, or high use ≥4 days/week and ≥3 years. Lung cancer cases (n = 808) were ascertained through linkage to the Surveillance, Epidemiology, and End Results cancer registry. Results: High 10-year use of glucosamine [hazard ratio (HR), 0.77; 95% CI: 0.56-1.07; p trend = 0.04] but not chondroitin was associated with a reduction in lung cancer risk. The association with glucosamine was limited to adenocarcinoma (HR, 0.49; 95% CI: 0.27-0.90; p trend <0.01) and was not modified by NSAID use or smoking status. Conclusions: Our results for glucosamine use are similar to the prior human studies of NSAID use and lung cancer, both in magnitude and the limitation of the association to adenocarcinoma. Unlike NSAIDs, glucosamine has no known adverse effects. Although confirmatory studies are needed, glucosamine is an attractive candidate for lung cancer chemoprevention.
AB - Objective: Inflammation plays an important role in lung carcinogenesis. Epidemiologic studies have reported inverse associations of non-steroidal anti-inflammatory drug (NSAID) use and lung cancer risk. Previously, we found that ever use of glucosamine and chondroitin, which have anti-inflammatory properties, were inversely associated with lung cancer risk. After an additional year of follow-up, we further examined the association including frequency/duration of use, interaction with factors associated with inflammation, and lung cancer histology. Methods: Participants were members of the VITamins And Lifestyle cohort. Adults, aged 50-76 years, who were residents of western Washington State, completed a baseline questionnaire in 2000-2002 (n = 76,904). Participants were queried on their use of glucosamine and chondroitin, over the 10 years prior to baseline, and categorized as nonuser, low use <4 days/week or <3 years, or high use ≥4 days/week and ≥3 years. Lung cancer cases (n = 808) were ascertained through linkage to the Surveillance, Epidemiology, and End Results cancer registry. Results: High 10-year use of glucosamine [hazard ratio (HR), 0.77; 95% CI: 0.56-1.07; p trend = 0.04] but not chondroitin was associated with a reduction in lung cancer risk. The association with glucosamine was limited to adenocarcinoma (HR, 0.49; 95% CI: 0.27-0.90; p trend <0.01) and was not modified by NSAID use or smoking status. Conclusions: Our results for glucosamine use are similar to the prior human studies of NSAID use and lung cancer, both in magnitude and the limitation of the association to adenocarcinoma. Unlike NSAIDs, glucosamine has no known adverse effects. Although confirmatory studies are needed, glucosamine is an attractive candidate for lung cancer chemoprevention.
KW - Adenocarcinoma
KW - Chondroitin
KW - Glucosamine
KW - Non-small-cell lung cancer
KW - Small-cell lung cancer
KW - Supplement
UR - http://www.scopus.com/inward/record.url?scp=80052326857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052326857&partnerID=8YFLogxK
U2 - 10.1007/s10552-011-9806-8
DO - 10.1007/s10552-011-9806-8
M3 - Article
C2 - 21706174
AN - SCOPUS:80052326857
SN - 0957-5243
VL - 22
SP - 1333
EP - 1342
JO - Cancer Causes and Control
JF - Cancer Causes and Control
IS - 9
ER -